The Repurposing Drugs in Oncology (ReDO) Project

ecancermedicalscience

Volumn 8, Issue 1, 2014, Pages

  Pantziarka, Pan ^a,b   Bouche, Gauthier ^a   Meheus, Lydie ^a   Sukhatme, Vidula ^c   Sukhatme, Vikas P ^c,d  

^a Anticancer Fund   (Belgium)

^b George Pantziarka TP53 Trust   (United Kingdom)

^c GlobalCures Inc   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Drug development; Drug repurposing; Health economics; Health policy; Metronomics; ReDO project

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; CELECOXIB; CHLOROQUINE; CIMETIDINE; CLARITHROMYCIN; CYTOTOXIC AGENT; DICLOFENAC; DOCOSAHEXAENOIC ACID; FLUINDOSTATIN; GENERIC DRUG; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ITRACONAZOLE; KETOROLAC; LOSARTAN; MEBENDAZOLE; METFORMIN; OMEPRAZOLE; POLYSACCHARIDE; POLYUNSATURATED FATTY ACID; PROPRANOLOL;

CLINICAL PRACTICE; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG LEGISLATION; DRUG REPOSITIONING; HEALTH CARE; HUMAN; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84904250476     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2014.442     Document Type: Review

References (58)

1. Scannell JW et al Diagnosing the decline in pharmaceutical R&D efficiency Nat Rev Drug Discov 11(3) pp 191-200 PMID: 22378269
2. Pammolli F, Magazzini L and Riccaboni M (2011) The productivity crisis in pharmaceutical R&D Nat Rev Drug Discov 10(6) pp 428-38 DOI: 10.1038/nrd3405 PMID: 21629293
3. Elebring T, Gill A and Plowright AT (2012) What is the most important approach in current drug discovery: doing the right things or doing things right? Drug Discov Today 17(21-22) pp 1166-9 DOI: 10.1016/j.drudis.2012.04.009 PMID: 22569181
4. Paul SM et al (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat Rev Drug Discov 9(3) pp 203-14 PMID: 20168317
5. Hay M et al (2014) Clinical development success rates for investigational drugs Nat Biotechnol 32(1) pp 40-51 DOI: 10.1038/nbt.2786 PMID: 24406927
6. Kaitin KI and DiMasi J a (2011) Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009 Clin Pharmacol Therapeutics 89(2) pp 183-8 DOI: 10.1038/clpt.2010.286
7. Bray F et al (2012) Global cancer transitions according to the human development index (2008-2030): a population-based study Lancet Oncol 13(8) pp 790-801 DOI: 10.1016/S1470-2045(12)70211-5 PMID: 22658655
8. Jemal A, Center MM, DeSantis C and Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends Cancer Epidemiol Biomarkers Prev 19(8) pp 1893-907 DOI: 10.1158/1055-9965.EPI-10-0437 PMID: 20647400
9. Vineis P and Wild CP (2014) Global cancer patterns: causes and prevention Lancet 383(9916) pp 549-57 DOI: 10.1016/S0140-6736(13)62224-2
10. Crawford S (June 25 2013) Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy Front Pharmacol, 4 p. 68 DOI: 10.3389/fphar.2013.00068 PMID: 23805101 PMCID: 3691519
11. Fojo T and Parkinson DR (2010) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 16(24) pp 5972-80 DOI: 10.1158/1078-0432.CCR-10-1277 PMID: 21169250
12. Huang M et al (2014) Molecularly targeted cancer therapy: some lessons from the past decade Trends Pharmacological Sci 35(1) pp 41-50 DOI: 10.1016/j.tips.2013.11.004
13. Gerlinger M et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing New Eng J Med 366(10) pp 883-92 DOI: 10.1056/NEJMoa1113205 PMID: 22397650
14. Fisher R, Pusztai L and Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics Br J Cancer 108(3) pp 479-85 DOI: 10.1038/bjc.2012.581 PMID: 23299535 PMCID: 3593543
15. Gerlinger M and Swanton C (2010) How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine British J Cancer 103(8) pp 1139-43 DOI: 10.1038/sj.bjc.6605912
16. Gillies RJ, Verduzco D and Gatenby R a (2012) Evolutionary dynamics of carcinogenesis and why targeted therapy does not work Nat Rev Cancer 12(7) pp 487-493 DOI: 10.1038/nrc3298 PMID: 22695393
17. Epstein RJ (2013) The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe Front Oncol, 12 (3) pp 304
18. André F et al (2014) Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) Lancet Oncol 15(3) pp 267-74 DOI: 10.1016/S1470-2045(13)70611-9 PMID: 24508104
19. Li F, Zhao C and Wang L (2014) Molecular-targeted agents combination therapy for cancer: developments and potentials Int J Cancer 134(6) pp 1257-69 DOI: 10.1002/ijc.28261
20. Vera-Badillo FE et al (2013) Benefit and harms of new anti-cancer drugs Curr Oncol Rep 15(3), pp. 270-5 DOI: 10.1007/s11912-013-0303-y PMID: 23435854
21. Li X et al (2013) Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials PloS One 8(11), p e81897 DOI: 10.1371/journal.pone.0081897 PMID: 24312376 PMCID: 3842967
22. Sacher AG, Le LW and Leighl NB (2014) Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non-Small-Cell Lung Cancer: The Bar Is Dropping J Clin Oncol 32(14)pp 1407-11 DOI: 10.1200/JCO.2013.52.7804 PMID: 24590634
23. Amit L et al (2013) The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors-a meta-analysis and systematic review PloS One 8(1) pp e51780 DOI: 10.1371/journal.pone.0051780 PMID: 23349675 PMCID: 3551962
24. Niraula S et al (2012) The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs J Clini Oncol 30(24) pp 3012-9 DOI: 10.1200/JCO.2011.40.3824
25. Chabner BA and Roberts TG (2005) Timeline: Chemotherapy and the war on cancer Nat Rev Cancer 5(1) pp 65-72 DOI: 10.1038/nrc1529 PMID: 15630416
26. Ashburn TT and Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs Nature Rev Drug Discov 3(8) pp 673-83 DOI: 10.1038/nrd1468 (Pubitemid 39173508)
27. Ghofrani HA, Osterloh IH and Grimminger F (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond Nat Rev Drug Discov 5(8) pp 689-702 DOI: 10.1038/nrd2030 PMID: 16883306 (Pubitemid 44151606)
28. Anon (2013) The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Blood 121(22) pp 4439-42 DOI: 10.1182/blood-2013- 03-490003
29. Aranda F et al (2014) Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy Oncoimmunology 3(1) pp e27297 DOI: 10.4161/onci.27297 PMID: 24701370 PMCID: 3961485
30. Nars MS and Kaneno R (2013) Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy Intl J Cancer 132(11) pp 2471-8 DOI: 10.1002/ijc.27801
31. Pasquier E et al (2011) Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology Transl Oncol 4(4) pp 203-11 DOI: 10.1593/tlo.11124 PMID: 21804915 PMCID: 3140007
32. Lien K et al (2013) Low-dose metronomic chemotherapy: a systematic literature analysis Eur J Cancer 49(16) pp 3387-95 DOI: 10.1016/j.ejca.2013.06. 038 PMID: 23880474
33. Scharovsky OG, Mainetti LE and Rozados VR (2009) Metronomic chemotherapy: changing the paradigm that more is better Curr Ooncology 16(2) pp 7-15.
34. Drevs J et al (2004) Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy Anticancer Res 24(3a) pp 1759-63 PMID: 15274352 (Pubitemid 38954706)
35. Quail DF and Joyce J a (2013) Microenvironmental regulation of tumor progression and metastasis Nat Med 19(11) pp 1423-37 DOI: 10.1038/nm.3394 PMID: 24202395 PMCID: 3954707
36. Kareva I (2011) What can ecology teach us about cancer? Transl Oncol 4(5) pp 266-70 DOI: 10.1593/tlo.11154 PMID: 21966543 PMCID: 3162301
37. Pienta KJ, McGregor N, Axelrod R and Axelrod DE (2008) Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments Transl Oncol 1(4) pp 158-64. DOI: 10.1593/tlo.08178 PMID: 19043526 PMCID: 2582164
38. Hahnfeldt P, Folkman J and Hlatky L (2003) Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis J Theoretical Biol 220(4) pp 545-54. DOI: 10.1006/jtbi.2003.3162 (Pubitemid 36293163)
39. Abdollahi A and Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy Drug Resist Updat 13(1-2) pp 16-28 DOI: 10.1016/j.drup.2009.12.001 PMID: 20061178
40. Pasquier E, Kavallaris M and André N (2010) Metronomic chemotherapy: new rationale for new directions Nat Rev Clin Oncol 7(8) pp 455-65 DOI: 10.1038/nrclinonc.2010.82 PMID: 20531380
41. Yin M, Zhou J, Gorak EJ and Quddus F (2013) Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis Oncologist 18(12) pp 1248-55 DOI: 10.1634/theoncologist.2013-0111 PMID: 24258613 PMCID: 3868417
42. Gallagher EJ and LeRoith D (2011) Diabetes, cancer, and metformin: connections of metabolism and cell proliferation Ann N Y Acad Sci 1243 pp 54-68. DOI: 10.1111/j.1749-6632.2011.06285.x
43. Pierotti MA et al (2013) Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects Oncogene 32(12) pp 1475-87. DOI: 10.1038/onc.2012.181
44. Dowling RJO et al (2012) Metformin in cancer: translational challenges J Mol Endocrinol 48(3) pp R31-43. DOI: 10.1530/JME-12-0007 PMID: 22355097
45. Phillips I et al (2013) Aspirin as a treatment for cancer Clin Oncol (R Coll Radiol) 25(6) pp 333-5 DOI: 10.1016/j.clon.2013.03.001
46. Bastiaannet E et al (2012) Use of Aspirin postdiagnosis improves survival for colon cancer patients Br J Cancer 106(9) pp 1564-70 DOI: 10.1038/bjc.2012.101 PMID: 22454078 PMCID: 3341868
47. Burn J et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial Lancet 378(9809) pp 2081-7 DOI: 10.1016/S0140-6736(11)61049-0 PMID: 22036019 PMCID: 3243929
48. Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer The N Engl J Med 348(10) pp 883-90 DOI: 10.1056/NEJMoa021633 (Pubitemid 36297996)
49. Sukhatme VP et al (2014) Financial Orphan Therapies Looking For Adoption, Health Affairs. [online] Available from: http://healthaffairs.org/blog/2014/03/ 06/financial-orphan-therapies-looking-for-adoption/ (Accessed 27 March 2014)
50. Sobrero A and Bruzzi P (2009) Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval Journal Clinical Oncol 27(35) pp 5868-73 DOI: 10.1200/JCO.2009.22.4162
51. Sherman RE et al (2013) Expediting drug development-the FDA's new "breakthrough therapy" designation N Engl J Med 369(20) pp 1877-80. DOI: 10.1056/NEJMp1311439 PMID: 24224621
52. Kubecova M et al (2011) Cimetidine: an anticancer drug? Europ J Pharm Sci 42(5) pp 439-44 DOI: 10.1016/j.ejps.2011.02.004
53. Deva S and Jameson M (2012) Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer The Cochrane Database Syst Rev 8 pp CD007814
54. Rudin CM et al (2013) Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer J Thorac Ooncol 8(5) pp 619-23
55. Yasuda H et al (2006) Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer J Clin Oncol 24(4) pp 688-94 DOI: 10.1200/JCO.2005.04.0436 PMID: 16446342 (Pubitemid 46630435)
56. Cole BF et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials J Natl Cancer Inst 101(4) pp 256-66 DOI: 10.1093/jnci/djn485 PMID: 19211452
57. Labianca R et al (2013) Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 24(Suppl 6) pp vi64-72 DOI: 10.1093/annonc/mdt354 PMID: 24078664
58. Demonaco HJ, Ali A and Hippel E Von (2006) The major role of clinicians in the discovery of off-label drug therapies Pharmacotherapy, 26(3) pp 323-32 DOI: 10.1592/phco.26.3.323 PMID: 16503712 (Pubitemid 43334671)